Why Training is the Key to Successful Guideline Implementation A. David PaltielPeter J. Neumann Current Opinion 15 November 2012 Pages: 297 - 302
The Economic Potential of Tamoxifen Prophylaxis in Breast Cancer James R. G. Butler Current Opinion 15 November 2012 Pages: 303 - 306
Strategies to Improve the Cost Effectiveness of General Practitioner Prescribing Hugh McGavock Leading Article 15 November 2012 Pages: 307 - 311
The US Orphan Drug Programme Sheila R. ShulmanMichael Manocchia Review Article 15 November 2012 Pages: 312 - 326
Economics of Home Parenteral Nutrition Alan CadeJohn Puntis Review Article 15 November 2012 Pages: 327 - 338
Drug Rationing in the UK National Health Service Tom WalleyAlan HaycoxStuart Barton Review Article 15 November 2012 Pages: 339 - 350
Treatment Costs and Quality of Life with Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Antineoplastic Therapy—Related Febrile Neutropenia Carin A. Uyl-de GrootEdo VellengaFrans F. H. Rutten Original Research Article 15 November 2012 Pages: 351 - 360
Cost Effectiveness of Hepatitis A Virus Immunisation in Spain José M. ArnalOlga FrisasFernando Antoñanzas Original Research Article 15 November 2012 Pages: 361 - 373
Cost-Effective Treatment of Uncomplicated Gonorrhoea Including Co-Infection with Chlamydia trachomatis Mehmet GençPer-Anders Mårdh Original Research Article 15 November 2012 Pages: 374 - 383
A Predictive Model of the Health Benefits and Cost Effectiveness of Celiprolol and Atenolol in Primary Prevention of Cardiovascular Disease in Hypertensive Patients Richard J. MilneStephen Vander HoornRodney T. Jackson Original Research Article 15 November 2012 Pages: 384 - 408
Dornase Alfa Karen L. GoaHarriet Lamb Adis Pharmacoeconomic Drug Evaluation 15 November 2012 Pages: 409 - 422